Acura Pharmaceuticals

Another stock that's just starting to trigger a near-term breakout trade is Acura Pharmaceuticals ( ACUR), which is engaged in the research, development and manufacture of product candidates providing abuse deterrent features and benefits. This stock has been in play with the bulls over the last six months, with shares up 24%.

If you look at the chart for Acura Pharmaceuticals, you'll notice that this stock recently formed a double bottom chart pattern at $1.95 to $2 a share. Shares of ACUR have now started to spike back above both its 200-day moving average at $2.08 and its 50-day moving average of $2.17 a share. This stock is also starting to break out above a key downtrend line that has acted as resistance for over the last month.

Traders should now look for long-biased trades in ACUR if it manages to break out above some near-term overhead resistance levels at $2.27 to $2.40 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average volume of 348,892 shares. If that breakout triggers soon, then ACUR will set up to re-test or possibly take out its next major overhead resistance levels at $2.79 to $3 a share. Any high-volume move above those levels will then put its recent super spike high of $3.62 into range for shares of ACUR.

This stock is a favorite target of the bears, since the current short interest as a percentage of the float for ACUR is pretty high at 12.5%. If that breakout triggers soon, we could easily get a large short-squeeze, so make sure to put ACUR on your breakout trading radar.

At last check, ACUR has hit an intraday high of $2.34 a share and volume is tracking just a bit below its three-month average action with around 240,000 shares traded.

Traders can look to buy ACUR off any weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support at its 200-day of $2.08 to $2 a share. One could also buy ACUR off strength once it takes out those breakout levels with volume and then simply use a stop just below its 50-day at $2.17 or its 200-day at $2.08 a share.

If you liked this article you might like

Mallinckrodt Is Just One Of Dennis Kozlowski's Billion Dollar Babies

Mallinckrodt Inks $1.3B Deal for Cadence

Mallinckrodt Buys Cadence Pharma for $1.3 Billion

Biotech Stocks Partying Like It's 1999

8 Stocks Under $10 Trending Sharply Higher